VETOQUINOL SA |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 102 EUR | +0.39% |
|
-2.86% | -0.39% |
| Apr. 30 | Vetoquinol: down after sales update | CF |
| Apr. 29 | Vetoquinol SA Reports Sales Results for the First Quarter of Fiscal 2024 | CI |
| Sales 2024 * | 551M 597M | Sales 2025 * | 577M 626M | Capitalization | 1.21B 1.31B |
|---|---|---|---|---|---|
| Net income 2024 * | 56M 60.73M | Net income 2025 * | 61M 66.15M | EV / Sales 2024 * | 1.86 x |
| Net cash position 2024 * | 183M 199M | Net cash position 2025 * | 235M 254M | EV / Sales 2025 * | 1.68 x |
| P/E ratio 2024 * |
21.3
x | P/E ratio 2025 * |
19.7
x | Employees | 2,440 |
| Yield 2024 * |
0.76% | Yield 2025 * |
0.82% | Free-Float | 32.57% |
More Fundamentals
* Assessed data
More news
More recommendations
More press releases
More news
| 1 day | +0.39% | ||
| 1 week | -2.86% | ||
| 1 month | +8.17% | ||
| 3 months | +1.59% | ||
| 6 months | +6.69% | ||
| Current year | -0.39% |
1 week
100.60
105.80
1 month
93.80106.00
Current year
92.60110.00
1 year
76.30110.00
3 years
76.30161.00
5 years
41.90161.00
10 years
32.10161.00
| Managers | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 55 | 01-04-01 | |
| Director of Finance/CFO | 59 | - | |
Philippe Gruet
CTO | Chief Tech/Sci/R&D Officer | - | 21-02-28 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Étienne Frechin
BRD | Director/Board Member | 86 | 62-07-01 |
| Chief Executive Officer | 55 | 01-04-01 | |
Philippe Arnold
BRD | Director/Board Member | 83 | 07-06-03 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.00% | 34 M€ | +3.86% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-31 | 102 | +0.39% | 1,335 |
| 24-05-30 | 101.6 | -.--% | 1,324 |
| 24-05-29 | 101.6 | -.--% | 2,205 |
| 24-05-28 | 101.6 | -2.31% | 3,195 |
| 24-05-27 | 104 | -0.95% | 1,540 |
Real-time Euronext Paris, May 31, 2024 at 11:35 am EDT
More quotes
Vetoquinol SA specializes in the research, development, production and marketing of veterinary drugs and products for pets (67.7% of net sales; dogs, cats, etc.) and livestock (32.3%; cattle, pigs, poultry, etc.). The group's activity is organized around 4 product families:
- antibiotics;
- anti-inflammatories;
- cardiology and nephrology treatments;
- other: anti-parasitics, vaccines, and nutritional products.
At the end of 2022, the group had 5 production sites throughout the world.
Net sales are distributed geographically as follows: Europe (46.7%), the Americas (36%) and Asia/Pacific (17.3%).
Sector
Pharmaceuticals
Calendar
2024-06-03
- Ex-dividend day for final dividend
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
HOLD
Number of Analysts
6
Last Close Price
102
EUR
Average target price
105.8
EUR
Spread / Average Target
+3.76%
EPS Revisions
Quarterly revenue - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -0.39% | 1.31B | |
| -14.09% | 77.37B | |
| +18.66% | 8.74B | |
| +23.75% | 3.67B | |
| -0.42% | 3.25B | |
| +18.07% | 1.73B | |
| -16.99% | 1.38B | |
| -26.05% | 1.24B | |
| -17.86% | 1.07B | |
| -6.77% | 976M |
- Stock Market
- Equities
- VETO Stock
